Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons?

导出原文传递

翻译打印收藏纠错

第一作者： Angioletta,Lasagna

第一单位： Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, Italy.

作者： Angioletta,Lasagna ^[1] ; Valentina,Zuccaro ^[2] ; Paolo,Sacchi ^[2] ; Silvia,Chiellino ^[1] ; Raffaele,Bruno ^[3] ; Paolo,Pedrazzoli ^[4]

作者单位： Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, Italy. ^[1] Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, Italy. ^[2] Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, Italy.;Department of Clinical, Surgical, Diagnostic & Pediatric Sciences, University of Pavia, Viale Camillo Golgi 19, Pavia, Italy. ^[3] Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, Italy.;Department of Internal Medicine & Medical Therapy, University of Pavia, Viale Camillo Golgi 19, Pavia, Italy. ^[4]

关键词 Covalently closed circular DNA OBI Occult hepatitis B cancer patients immune checkpoint inhibitors immunotherapy prophylactic therapy reactivation

主题词乙型肝炎病毒(Hepatitis B virus);乙型肝炎, 慢性(Hepatitis B, Chronic);人类(Humans);免疫减弱宿主(Immunocompromised Host);肿瘤(Neoplasms);患病率(Prevalence);病毒激活(Virus Activation)

DOI 10.2217/fon-2020-1196

PMID 33590770

发布时间 2021-11-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交